Clinical Oncology

[The role of next-generation sequencing in clinival oncology]

KOTMAYER Lili1,2, BÖDÖR Csaba1,2

JUNE 30, 2021

Clinical Oncology - 2021;8(2)

[Over the past decade next-generation sequencing has led to the in-depth understanding of the molecular background and driving mechanisms in most types of cancer. Parallel to the technological advances, novel targeted therapies have become available for oncology patients. As a result of this process, molecular diagnostics is now one of the main cornerstones of precision medicine with predictive biomarkers aiding patient care in oncology. In addition to standard monogenic testings, recently multigene testing methods based on next-generation sequencing came into view, supporting targeted therapeutic decisions and personalized medicine. In this review, we aim to depict the most important professional aspects related to the reasonable application of next-generation sequencing and the interpretation of its results.]

AFFILIATIONS

  1. HCEMM-SE Molekuláris Onkohematológia Kutatócsoport, Budapest
  2. I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Relevance of adrenal insufficiency in the management of oncological patients]

IGAZ Péter

[Adrenal insufficiency has a complex relevance in oncology. On one hand, malignant tumors warranting treatment might develop in patients suffering from adrenal insufficiency, on the other hand, adrenal insufficiency might appear due to the progression of malignant tumor or to its therapy. During the progression of oncological disease, bilateral adrenal or very rarely pituitary metastases could result in adrenal insufficiency. Novel immune-checkpoint inhibitors, opioids and long-term glucocorticoid treatment can all lead to adrenal insufficiency. It is very important to recognize and to know the treatment of adrenal insufficiency, as failure of treating adrenal insufficiency might be related to severe, even fatal consequences. In this review, these clinically relevant fields are presented.]

Clinical Oncology

[Combining angiogenesis- and checkpoint-inhibitors to potentiate each other’s effects]

PIKÓ Béla, BASSAM Ali, MARIK László

[Both, the inhibition of angiogenesis and the influence of immune-mediated processes play significantly growing role in non-surgical treatment of tumors. Neoangiogenesis of neoplasmas adversely affects the function of the immune system, so its inhibition enhances the action of T-lymphocytes and other factors that support their function, favorably affects the microenvironment of the tumor, while treatment with immune signaling sites helps to normalize the vascular system. Influencing those two targeting points together may have a beneficial effect. Authors present that the combined use of agents having those two targets in renal cell carcinoma, melanoma malignum, non-small cell lung cancer, colorectal cancer, hepatocellular and breast cancer noting that successful phase III studies have been performed predominantly in clear cell (or tumor that also contains a clear cell component) carcinomas. The authors emphasize that immunotherapy usually requires the detection of susceptibility-predicting parameters (corresponding PD-L1, MSI-H, dMMR, TMB-H) and that registered indications should be considered in addition to the therapeutic philosophy of tumor agnostic treatment.]

Clinical Oncology

[Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine]

CASOLINO R, BRACONI C, MALLEO G, PAIELLA S, BASSI G, MILELLA M, DREYER S B, FROELING FE M, CHANG D K, BIANKIN A V, GOLAN T

[Summary – This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.]

Clinical Oncology

[Microsatellites act as „seismographs” of the genome]

SÜKÖSD Farkas

[Short non-protein-coding repetitive regions consisting of 1-6 bp sequences are called microsatellites. Failure in DNA polymerase activity during replication may lead to an increase or reduction in the number of these repeats. Generally, these microsatellite number variations are corrected via the DNA repair machinery; if not, the alterations are transmitted to the progeny, which is also indicated by the elevated mutation rate in the offspring. Microsatellite instability (MSI) can also cause reading-frame problems, and this can lead to elevated expression of foreign antigens in tumors, promising an enhanced efficacy of the anti-tumour immune response. Thus, MSI indicates not only genetic instability but also an increased efficacy of immune checkpoint inhibitors. Various tools such as PCR-based techniques or immunohistochemical methods have been developed to confirm MSI and to examine the functionality of the DNA repair mechanisms in these patients. Additionally, the recent technology also allows us to examine of microsatellites by using next-generation sequencing or artificial intelligence-based image analysis methods. In this review, we summarize recent methodologies and the clinical significance of MSI analysis. ]

Clinical Oncology

[EMDR therapy in the treatment of oncology patients]

HAVELKA Judit

[The diagnosis and treatment of a life-threatening disease such as cancer involves exposure to psychological and physical stress and may constitute a traumatic experience for most people. Abnormal adaptation of neurobiological systems to the stress following experienced trauma, furthermore, individual fac­tors such as previous traumas may also play a role in PTSD development. In the context of oncology, there is a specific need to develop better tools for psychological assessment, that address cancer-related stressors. It is hypothesized that eye movement desensitization and reprocessing (EMDR) therapy promotes the elicitation of the innate self-healing capacity, the natural healing process of the immune system and adaptive information reprocessing. The EMDR therapeutic intervention with oncological patients aims to repair the psychic balance, empower resilience factors and to allow the processing of traumatic disease-related experiences.]

All articles in the issue

Related contents

Lege Artis Medicinae

[ALTERATIONS IN MYOCARDIAL CONTRACTILE PROTEIN COMPOSITION IN DIASTOLIC HEART FAILURE]

PAPP Zoltán, BORBÉLY Attila, ÉDES István

[Disturbances in ventricular relaxation may lead to the development of diastolic heart failure. The analysis of left ventricular endomyocardial biopsy specimens may help understand the underlying structural and functional changes. Such analyses have lead to the recognition that at the optimal sarcomere length of the Frank- Starling mechanism (i.e., at 2.2 μm), passive force values of the cardiomyocytes are significantly higher in individuals with diastolic heart failure than in healthy controls. As a probable explanation to this finding, increased expression of the stiffer N2B isoform of the myofilamental titin protein, at the expense of the more elastic N2BA titin isoform, has been recognized. Moreover, decreased phosphorylation of the contractile proteins was also suggested to contribute to the development of diastolic heart failure. These changes together, and along with an increase in extracellular collagen content, may greatly contribute to the relaxation disturbance observed in diastolic heart failure.]

Clinical Oncology

[Adjuvant chemotherapy for operable breast cancer]

NAGYKÁLNAI Tamás, LANDHERR László

[The use of adjuvant chemotherapy in early stage breast cancer has made signifi cant progress in the last decades. This review will focus on the benefi cial effects of different chemotherapy regimens on the risk of recurrence and breast cancer mortality.]

Clinical Oncology

[Diagnosis and therapy of childhood brain tumors – an update]

GARAMI Miklós

[Childhood cancers are rare disorders. The average annual age-standardized incidence is 149/1000000 (0-14 yrs). Diagnosis of childhood brain tumors, despite the specifi c localization and advanced imaging techniques can cause diffi culties. In recent years, due to better early recognition, number of surgically removable brain tumors is increasing. Early detection of the disease (clinical knowledge), use of modern imaging (fMRI) techniques and detection of characteristic molecular lesions allow up-to-date diagnosis and successful treatments. These approaches provide the basis for risk-adapted personalized treatment options]

Clinical Oncology

[The use of NGS in oncology in diagnostic setting]

BECSÁGH Péter

[Today the information could be the basis of further development by collecting, saving, structuring and analyzing them. Inside the living organism and inside viruses the biochemical storage system was evolved. The linear coding inside macromolecular structures could create and store a series of building block combinations along the chain structure. Those chemical structures are the so called information coding macromolecules, for example, the polypeptides and nucleic acids. Analysis of the genetically coded functionalities of tumor cells has a great impact in the oncological setting. The connected functions of inherited or acquired alterations inside the tumor cell clones are the main contributors of tumor evolution and surviving, although provide a way to target possible mechanism and touch points. Today the oncodiagnostic use of next generation sequencing technology focus on tumor evolution and tumor surviving connected gene set analysis. This kind of gene panel analysis connected to NGS technology is enough enforced - enforced enough - to reach the diagnostic level, but one still need to take care about the quality and standardization to meet the IVD conditions.]

Clinical Oncology

[Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine]

CASOLINO R, BRACONI C, MALLEO G, PAIELLA S, BASSI G, MILELLA M, DREYER S B, FROELING FE M, CHANG D K, BIANKIN A V, GOLAN T

[Summary – This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalised therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of ‘all-comer’ treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalised treatment allocation has the substantial potential to reduce pancreatic cancer mortality.]